Jake Fishman - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jake Fishman's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jake Fishman
Verified
Editor, Cardiac Wire
San Diego, Zhengzhou
Beats
Drawing , Current Events, Politics , Science, Art, Health Tech, Photography
Content
By Jake Fishman| Cardiac Wire@ Topline results from NewAmsterdam’s Phase 3 BROADWAY trial provided the strongest evidence yet of obicetrapib’s potential for patients with ASCVD and heterozygous familial hypercholesterolemia (HeFH) who can’t lower their LDL-C with statins. HeFH affects 1 in 250 people worldwide and often makes statin-based LDL-C therapies ineffective due to naturally raising patients’ blood lipid levels.
By Jake Fishman| Cardiac Wire@ Topline results from the SURMOUNT-5 trial found Eli Lilly’s tirzepatide led to far greater weight loss than Novo Nordisk’s semaglutide, giving Lilly a boost in the race to become America’s go-to GLP-1. Semaglutide and tirzepatide both originally received FDA approval for treating adults with T2D, with those approvals later extending to weight loss management. Both drugs mimic the GLP-1 hormone, but tirzepatide also mimics another metabolic hormone called GIP.
By Jake Fishman| Cardiac Wire@ Topline results from NewAmsterdam’s Phase 3 BROADWAY trial provided the strongest evidence yet of obicetrapib’s potential for patients with ASCVD and heterozygous familial hypercholesterolemia (HeFH) who can’t lower their LDL-C with statins. HeFH affects 1 in 250 people worldwide and often makes statin-based LDL-C therapies ineffective due to naturally raising patients’ blood lipid levels.
Company Info
Cardiac Wire